Accepted for Publication: December 18, 2013.
Study concept and design: Pittock, Lennon, Lucchinetti, Lisak.
Acquisition of data: Figueroa, Guo, Tselis, Lennon, Lucchinetti.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Figueroa, Guo, Tselis, Lisak.
Critical revision of the manuscript for important intellectual content: All authors.
Obtained funding: Pittock, Lennon, Lucchinetti, Lisak.
Conflict of Interest Disclosures: Dr Tselis has received research funding from Acorda, Biogen Idec, Genzyme, Novartis, Roche, and Teva. Dr Pittock is a named inventor on patents (12/678,350 filed 2010 and 12/573,942 filed 2008) that relate to functional aquaporin-4 (AQP4)/neuromyelitis optica (NMO) IgG assays and NMO IgG as a cancer marker. He has provided consultation to Alexion Pharmaceuticals, Chugai Pharmaceutical, and MedImmune Inc but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to the Mayo Clinic. Dr Pittock receives research support from Alexion Pharmaceuticals Inc. Dr Lennon is a named inventor on a patent (7101679, issued 2006) relating to AQP4 antibodies for diagnosis of NMO and receives royalties for this technology. Dr Lennon is a named inventor on patents (12/678,350 filed 2010 and 12/573,942 filed 2008) that relate to functional AQP4/NMO IgG assays and NMO IgG as a cancer marker. Serological testing for neural autoantibodies is offered on a service basis by Mayo Collaborative Service Inc, an agency of the Mayo Foundation. Neither Dr Lennon nor her laboratory benefit financially from this testing. Dr Lucchinetti is a named inventor on patents (12/678,350 filed 2010 and 12/573,942 filed 2008) that relate to the function of AQP4/NMO-IgG assays and NMO IgG as a cancer marker. Dr Lisak has consulted for Teva Pharmaceuticals, Novartis, Geon, and Questcor. He has served as an expert witness and consultant in patent cases for Teva and is on a speakers list for nonpromotional talks for Teva. Dr Lisak has received research funding from Acorda, Avanir, Biogen Idec, Genzyme, Novartis, Questcor, Roche, and Teva. No other disclosures were reported.
Funding/Support: This work was supported by the Parker Webber Chair in Neurology Endowment, Detroit Medical Center Foundation/Wayne State University (Dr Lisak) and grants from the National Institutes of Health (RO-1-NS065829, Drs Pittock and Lennon) and the Guthy-Jackson Charitable Foundation (Drs Lucchinetti and Pittock).
Role of the Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.